SCHEMBL22819367

SCHEMBL22819367

Cc1ccc2[nH]nc(-c3ccc(CO)cc3)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 11/20 1.00
MAPK1 P28482 7/20 0.70
MAPKAPK3 Q16644 6/20 0.70
MAPK6 Q16659 6/20 0.70
MAPKAPK2 P49137 5/20 0.70
MAPKAPK5 Q8IW41 3/20 0.70
ITK Q08881 2/20 0.50
NTRK1 P04629 1/20 0.44
MKNK1 Q9BUB5 1/20 0.43
TTK P33981 1/20 0.43
FGFR1 P11362 1/20 0.42
DCLK1 O15075 1/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
CHEK2 O96017 1/20 0.42
CSF1R P07333 1/20 0.42
FER P16591 1/20 0.42
CDK2 P24941 1/20 0.42
MARK3 P27448 1/20 0.42
FLT4 P35916 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22819362 0.84 MAP2K4 (1.00) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
SCHEMBL22801614 0.83 MAP2K4 (1.00) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
SCHEMBL5374591 0.80 MAP2K4 (0.71) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
SCHEMBL4093740 0.79 MAP2K4 (0.71) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
SCHEMBL22819363 0.78 MAP2K4 (1.00) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
SCHEMBL8251865 0.77 MAP2K4 (0.68) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
SCHEMBL22819384 0.77 MAP2K4 (1.00) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
SCHEMBL5952447 0.76 MAP2K4 (0.60) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
SCHEMBL22801768 0.75 MAP2K4 (0.59) MAP2K4MAPK1MAPKAPK3MAPK6MAPKAPK2
SCHEMBL12907250 0.72 JAK2 (0.66) MAP2K4DCLK1PRKD3MAP4K4CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11370770-B2 3-arylindazoles as selective MEK4 inhibitors NORTHWESTERN UNIVERSITY (US) 2022-06-28 US disclosed
US-20200399241-A1 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS NORTHWESTERN UNIVERSITY (US) 2020-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399241-A1 3-ARYLINDAZOLES AS SELECTIVE MEK4 INHIBITORS MAP4K3, MAPK4, MAP3K4 MAP2K4 39/4885MAPK1 32/4885MAPKAPK3 24/4885
US-11370770-B2 3-arylindazoles as selective MEK4 inhibitors MAP4K3, MAPK4, MAP3K4 MAP2K4 39/4885MAPK1 32/4885MAPKAPK3 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.